Capsulin IR is under clinical development by Diabetology (Products) and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Capsulin IR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Capsulin IR overview
Capsulin IR (insulin replacement) is under development for the treatment of type 1 diabetes. Capsulin IR is an oral encapsulated formulation of recombinant human insulin which acts by targeting insulin receptor. Capsulin IR is developed using Axcess drug delivery technology. The Axcess delivery system increases the absorption of peptides, proteins and other macromolecules. It is an immediate release formulation.
Diabetology (Products) overview
Diabetology (Products) (Diabetology), a subsidiary of Proxima Concepts Ltd, is a biopharmaceutical company that develops oral drugs for the treatment of diabetes. The company provides oral delivery system to administer bioactive and compounds to transform the treatment outcomes for patients with diabetes. Its pipeline products include capsulin OAD, capsulin IR, oral GLP-1 analog and combulin. Diabetology offers axcess, a system that increases the absorption of peptides, proteins and other macromolecules. Its capsulin OAD is an oral anti-diabetic used in the treatment of type 2 diabetes mellitus and oral GLP-1 analog reduces glucose output from the liver and improves insulin sensitivity and the function of beta-cells. The company operates in the UK and Australia. Diabetology is headquartered in Jersey, the UK.
For a complete picture of Capsulin IR’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
